The effects of the PPAR-γ agonist pioglitazone on plasma concentrations of circulating vasoactive factors in type II diabetes mellitus

Journal of Human Hypertension

Volumn 24, Issue 1, 2010, Pages 74-76

  De Boer, R A ^a   Martens, F M A C ^b   Kuipers, I ^a   Boomsma, F ^c   Visseren, F L J ^d  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b DEVENTER HOSPITAL   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALDOSTERONE; AMINE OXIDASE (COPPER CONTAINING); ANTIDIABETIC AGENT; ATRIAL NATRIURETIC FACTOR; ENDOTHELIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; RENIN;

ARTICLE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG POTENTIATION; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL;

ALDOSTERONE; AMINE OXIDASE (COPPER-CONTAINING); ATRIAL NATRIURETIC FACTOR; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; ENDOTHELINS; HUMANS; HYPOGLYCEMIC AGENTS; PPAR GAMMA; RENIN; THIAZOLIDINEDIONES;

EID: 77449083692     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2009.84     Document Type: Article

References (12)

1. Martens FM, Visseren FL, Lemay J, de Koning EJ, Rabelink TJ. Metabolic and additional vascular effects of thiazolidinediones. Drugs 2002; 62: 1463-1480.
2. Walker AB, Chattington PD, Buckingham RE, Williams G. The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats. Diabetes 1999; 48: 1448-1453.
3. Grinsell JW, Lardinois CK, Swislocki A, Gonzalez R, Sare JS, Michaels JR et al. Pioglitazone attenuates basal and postprandial insulin concentrations and blood pressure in the spontaneously hypertensive rat. Am J Hypertens 2000; 13(4 Part 1): 370-375.
4. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-1289.
5. Komajda M, Curtis P, Hanefeld M, Beck-Nielsen H, Pocock SJ, Zambanini A et al. Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study). Cardiovasc Diabetol 2008; 7: 10.
6. Giles TD, Sander AG. Effects of thiazolidinediones on blood pressure. Curr Hypertens Rep 2007; 9: 332-337.
7. Martens FM, Visseren FL, de Koning EJ, Rabelink TJ. Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes. J Cardiovasc Pharmacol 2005; 46: 773-778.
8. Martens FM, Rabelink TJ, op ’t Roodt J, de Koning EJ, Visseren FL. TNF-alpha induces endothelial dysfunction in diabetic adults, an effect reversible by the PPAR-gamma agonist pioglitazone. Eur Heart J 2006; 27: 1605-1609.
9. Barroso I, Gurnell M, Crowley VE, Agostini M, Schwabe JW, Soos MA et al. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 1999; 402: 880-883.
10. Kuipers I, van der Harst P, Navis G, van Genne L, Morello F, van Gilst WH et al. Nuclear hormone receptors as regulators of the renin-angiotensin-aldosterone system. Hypertension 2008; 51: 1442-1448.
11. Lansang MC, Coletti C, Ahmed S, Gordon MS, Hollenberg NK. Effects of the PPAR-gamma agonist rosiglitazone on renal haemodynamics and the renin-angiotensin system in diabetes. J Renin Angiotensin Aldosterone Syst 2006; 7: 175-180.
12. Zanchi A, Chiolero A, Maillard M, Nussberger J, Brunner HR, Burnier M. Effects of the peroxisomal proliferator-activated receptor-gamma agonist pioglitazone on renal and hormonal responses to salt in healthy men. J Clin Endocrinol Metab 2004; 89: 1140-1145.